Athira Pharma Inc (ATHA)

Form 8-K - Current report

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Athira Pharma Shares Surge After Securing Rights to Phase 3 Breast Cancer Therapy

Athira Pharma Inc (NASDAQ:ATHA) shares soared 73.4% in premarket trading on Thursday after the clinical-stage biopharmaceutical company announced...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form 8-K - Current report